Antiretroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotype testing at the Central Public Health Laboratory, São Paulo, Brazil: Preliminary results

Memorias do Instituto Oswaldo Cruz

Volumn 100, Issue 1, 2005, Pages 97-102

  Rodrigues, Rosangela ^a   Pasquareli Vazquez, Carla Maria ^b   Colares, Jeova Keny ^c   Custodio, Renata Marconi ^a   Bonásser Filho, Francisco ^b   Do Rosário Souza, Lenice ^d   Gianna, Maria Clara ^e   De Azevedo Marques, Cristiano Corrêa ^a   De Macedo Brígido, Luís Fernando ^f  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

^b INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^c UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^e Ctro Referencia e Treinamento AIDS   (Brazil)

^f MINISTÉRIO DA SAÚDE   (Brazil)

Author keywords

Antiretroviral resistance; Brazil; Diversity; Human immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT; AZATHIOPRINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; VIRUS RNA;

BLOOD ANALYSIS; BLOOD SAMPLING; CODON; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; TREATMENT FAILURE; VIRUS GENE; VIRUS MUTATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 15244353678     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762005000100018     Document Type: Conference Paper

References (16)

1. Antinori A, Liuzzi G, Cingolani A, Bertoli A, Di Giambenedetto S, Trotta MP, Rizzo MG, Girardi E, De Luca A, Perno CF 2001. Drug resistance mutation of HIV-1 in patients exhibiting increasing CD4 cell counts despite virological failure of HAART. AIDS 15: 2325-2327.
2. Bongertz V, Bou-Habib DC, Brigido LF, Caseiro M, Chequer PJ, Couto-Fernandez JC, Ferreira PC, Galvao-Castro B, Greco D, Guimaraes ML, Linhares de Carvalho MI, Morgado MG, Oliveira CA, Osmanov S, Ramos CA, Rossini M, Sabino E, Tanuri A, Ueda M 2000. HIV-1 diversity in Brazil: genetic, biologic, and immunologic characterization of HIV-1 strains in three potential HIV vaccine evaluation sites. Brazilian Network for HIV Isolation and Characterization. J Acquir Immune Defic Syndr 23: 184-193.
3. Casseb J, Pereira Junior LC, Silva GL, Medeiros LA 1999. Decreasing mortality and morbidity in adult AIDS patients from 1995 to 1997 in Sao Paulo, Brazil. AIDS Patient Care STDS 13: 213-214.
4. Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro JM, Boucher CA, Dellamonica P 2000. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antivir Ther 5: 65-70.
5. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD, International AIDS Society-USA 2002. Drug Resistance Mutation in HIV-1. Topics in HIV Medicine 10: 21-25.
6. Deeks SG, Barbour J, Matin J, Swanson M, Grant RM 2000. Sustained CD4 T cell response after virologic failure of protease inhibitor based regimens in HIV infected patients. J Infect Dis 181: 946-953.
7. Larder BA, Kemp SD 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
8. Loutfy MR, Walmsley SL 2002. Salvage antiretroviral therapy in HIV infection. Expert Opin Pharmacother 3: 81-90.
9. Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, Chequer P, Teixeira PR, and Hearst N 2003. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 17: 1675-1682.
10. Ministério da Saúde, CN-DST/Aids, Brazil 2004. Recommendations for Antiretroviral therapy in HIV-infected adults and adolescents - 2002/2003. Available at http://www.aids.gov.br/final/tratamento/ consenso_english_2003.htm.
11. Montaner JSG, Harrigan PR, Jahnke N, Raboud J, Castillo E, Hogg RS, Yip B, Harris M, Montessori V, O'Shaughnessy MV 2001. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 15: 61-69.
12. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral activation transfusion study investigators 2001. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135: 17-26.
13. Nijhuis M, Deeks S, Boucher C 2001. Implications of antiretroviral resistance on fitness. Curr Opinion in Infec Dis 14: 23-28.
14. Sabino EC, Diaz RS, Brigido LF, Learn GH, Mullins JI, Reingold AL, Duarte AJ, Mayer A, Busch MP 1996. Distribution of HIV-1 subtypes seen in an AIDS clinic in Sao Paulo City, Brazil. AIDS 10: 1579-1584.
15. Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 169: 722-729.
16. Valer L, Gonzalez de Requena D, de Mendoza C, Martin-Carbonero L, Gonzalez-Lahoz J, Soriano V 2004. Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens. AIDS Patient Care STDs 18: 1-6.